Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 2245 to 2254 of 2254 entries
Sorted by: Best Match Show Resources per page
Donor CMV Reactivation as a Novel Risk Factor for CMV Replication in Seropositive Liver Transplant Recipients.

Transplantation direct

Limaye AP, Rahnemai-Azar AA, Nazarian SM, Perkins JD, Reyes JD.
PMID: 33324742
Transplant Direct. 2020 Dec 08;7(1):e637. doi: 10.1097/TXD.0000000000001083. eCollection 2021 Jan.

Risk factors for cytomegalovirus (CMV) viremia in CMV seropositive liver transplant recipients are incompletely defined and have focused primarily on recipient factors. We hypothesized that active CMV replication (CMV viremia) in seropositive donors might increase the risk for CMV...

Cite
Limaye AP, Rahnemai-Azar AA, Nazarian SM, et al. Donor CMV Reactivation as a Novel Risk Factor for CMV Replication in Seropositive Liver Transplant Recipients. Transplant Direct. 2020;7(1):e637doi: 10.1097/TXD.0000000000001083.
Limaye, A. P., Rahnemai-Azar, A. A., Nazarian, S. M., Perkins, J. D., & Reyes, J. D. (2021). Donor CMV Reactivation as a Novel Risk Factor for CMV Replication in Seropositive Liver Transplant Recipients. Transplantation direct, 7(1), e637. https://doi.org/10.1097/TXD.0000000000001083
Limaye, Ajit P, et al. "Donor CMV Reactivation as a Novel Risk Factor for CMV Replication in Seropositive Liver Transplant Recipients." Transplantation direct vol. 7,1 (2021): e637. doi: https://doi.org/10.1097/TXD.0000000000001083
Limaye AP, Rahnemai-Azar AA, Nazarian SM, Perkins JD, Reyes JD. Donor CMV Reactivation as a Novel Risk Factor for CMV Replication in Seropositive Liver Transplant Recipients. Transplant Direct. 2020 Dec 08;7(1):e637. doi: 10.1097/TXD.0000000000001083. eCollection 2021 Jan. PMID: 33324742; PMCID: PMC7725261.
Copy Download .nbib Format: NLM
Minimally invasive approach in endometrial cancer with lower uterine segment involvement in stage ≥ II: A retrospective study.

European journal of obstetrics, gynecology, and reproductive biology

Perri T, Levin G, Helpman L, Eitan R, Vaknin Z, Lavie O, Ben Arie A, Amit A, Levy T, Namazov A, Ben Shachar I, Atlas I, Bruchim I, Kogan L, Gemer O.
PMID: 34800816
Eur J Obstet Gynecol Reprod Biol. 2021 Nov 12;268:43-47. doi: 10.1016/j.ejogrb.2021.11.012. Epub 2021 Nov 12.

OBJECTIVE: To compare oncological outcomes in women with lower uterine segment involvement (LUSI) in endometrial carcinoma (EC) stage ≥ II - staged by a minimally invasive surgery (MIS) versus laparotomy.STUDY DESIGN: A retrospective multi-center cohort study. Univariate analysis, Kaplan-Meier...

Cite
Perri T, Levin G, Helpman L, et al. Minimally invasive approach in endometrial cancer with lower uterine segment involvement in stage ≥ II: A retrospective study. Eur J Obstet Gynecol Reprod Biol. 2021;268:43-47doi: 10.1016/j.ejogrb.2021.11.012.
Perri, T., Levin, G., Helpman, L., Eitan, R., Vaknin, Z., Lavie, O., Ben Arie, A., Amit, A., Levy, T., Namazov, A., Ben Shachar, I., Atlas, I., Bruchim, I., Kogan, L., & Gemer, O. (2021). Minimally invasive approach in endometrial cancer with lower uterine segment involvement in stage ≥ II: A retrospective study. European journal of obstetrics, gynecology, and reproductive biology, 26843-47. https://doi.org/10.1016/j.ejogrb.2021.11.012
Perri, Tamar, et al. "Minimally invasive approach in endometrial cancer with lower uterine segment involvement in stage ≥ II: A retrospective study." European journal of obstetrics, gynecology, and reproductive biology vol. 268 (2021): 43-47. doi: https://doi.org/10.1016/j.ejogrb.2021.11.012
Perri T, Levin G, Helpman L, Eitan R, Vaknin Z, Lavie O, Ben Arie A, Amit A, Levy T, Namazov A, Ben Shachar I, Atlas I, Bruchim I, Kogan L, Gemer O. Minimally invasive approach in endometrial cancer with lower uterine segment involvement in stage ≥ II: A retrospective study. Eur J Obstet Gynecol Reprod Biol. 2021 Nov 12;268:43-47. doi: 10.1016/j.ejogrb.2021.11.012. Epub 2021 Nov 12. PMID: 34800816.
Copy Download .nbib Format: NLM
High Neutrophil-Lymphocyte Ratio and Delta Neutrophil-Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer.

Digestive diseases and sciences

Rich NE, Parvathaneni A, Sen A, Odewole M, Arroyo A, Mufti AR, Kerr TA, Grant L, Tujios SR, Mayo MJ, Lee WM, Yang JD, Yokoo T, Gopal P, Hoshida Y, Zhu H, Yopp AC, Marrero JA, Singal AG.
PMID: 33939138
Dig Dis Sci. 2021 May 03; doi: 10.1007/s10620-021-07001-6. Epub 2021 May 03.

BACKGROUND: The neutrophil-lymphocyte ratio (NLR) has been proposed as a prognostic biomarker for cirrhosis and non-liver malignancies. We aimed to evaluate the prognostic value of NLR in a diverse cohort of patients with hepatocellular carcinoma (HCC).METHODS: We performed a...

Cite
Rich NE, Parvathaneni A, Sen A, et al. High Neutrophil-Lymphocyte Ratio and Delta Neutrophil-Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer. Dig Dis Sci. 2021;doi: 10.1007/s10620-021-07001-6.
Rich, N. E., Parvathaneni, A., Sen, A., Odewole, M., Arroyo, A., Mufti, A. R., Kerr, T. A., Grant, L., Tujios, S. R., Mayo, M. J., Lee, W. M., Yang, J. D., Yokoo, T., Gopal, P., Hoshida, Y., Zhu, H., Yopp, A. C., Marrero, J. A., & Singal, A. G. (2021). High Neutrophil-Lymphocyte Ratio and Delta Neutrophil-Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer. Digestive diseases and sciences, . https://doi.org/10.1007/s10620-021-07001-6
Rich, Nicole E, et al. "High Neutrophil-Lymphocyte Ratio and Delta Neutrophil-Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer." Digestive diseases and sciences vol. (2021). doi: https://doi.org/10.1007/s10620-021-07001-6
Rich NE, Parvathaneni A, Sen A, Odewole M, Arroyo A, Mufti AR, Kerr TA, Grant L, Tujios SR, Mayo MJ, Lee WM, Yang JD, Yokoo T, Gopal P, Hoshida Y, Zhu H, Yopp AC, Marrero JA, Singal AG. High Neutrophil-Lymphocyte Ratio and Delta Neutrophil-Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer. Dig Dis Sci. 2021 May 03; doi: 10.1007/s10620-021-07001-6. Epub 2021 May 03. PMID: 33939138.
Copy Download .nbib Format: NLM
A chickpea genetic variation map based on the sequencing of 3,366 genomes.

Nature

Varshney RK, Roorkiwal M, Sun S, Bajaj P, Chitikineni A, Thudi M, Singh NP, Du X, Upadhyaya HD, Khan AW, Wang Y, Garg V, Fan G, Cowling WA, Crossa J, Gentzbittel L, Voss-Fels KP, Valluri VK, Sinha P, Singh VK, Ben C, Rathore A, Punna R, Singh MK, Tar'an B, Bharadwaj C, Yasin M, Pithia MS, Singh S, Soren KR, Kudapa H, Jarquín D, Cubry P, Hickey LT, Dixit GP, Thuillet AC, Hamwieh A, Kumar S, Deokar AA, Chaturvedi SK, Francis A, Howard R, Chattopadhyay D, Edwards D, Lyons E, Vigouroux Y, Hayes BJ, von Wettberg E, Datta SK, Yang H, Nguyen HT, Wang J, Siddique KHM, Mohapatra T, Bennetzen JL, Xu X, Liu X.
PMID: 34759320
Nature. 2021 Nov;599(7886):622-627. doi: 10.1038/s41586-021-04066-1. Epub 2021 Nov 10.

Zero hunger and good health could be realized by 2030 through effective conservation, characterization and utilization of germplasm resources

Cite
Varshney RK, Roorkiwal M, Sun S, et al. A chickpea genetic variation map based on the sequencing of 3,366 genomes. Nature. 2021;599(7886):622-627doi: 10.1038/s41586-021-04066-1.
Varshney, R. K., Roorkiwal, M., Sun, S., Bajaj, P., Chitikineni, A., Thudi, M., Singh, N. P., Du, X., Upadhyaya, H. D., Khan, A. W., Wang, Y., Garg, V., Fan, G., Cowling, W. A., Crossa, J., Gentzbittel, L., Voss-Fels, K. P., Valluri, V. K., Sinha, P., Singh, V. K., Ben, C., Rathore, A., Punna, R., Singh, M. K., Tar'an, B., Bharadwaj, C., Yasin, M., Pithia, M. S., Singh, S., Soren, K. R., Kudapa, H., Jarquín, D., Cubry, P., Hickey, L. T., Dixit, G. P., Thuillet, A. C., Hamwieh, A., Kumar, S., Deokar, A. A., Chaturvedi, S. K., Francis, A., Howard, R., Chattopadhyay, D., Edwards, D., Lyons, E., Vigouroux, Y., Hayes, B. J., von Wettberg, E., Datta, S. K., Yang, H., Nguyen, H. T., Wang, J., Siddique, K. H. M., Mohapatra, T., Bennetzen, J. L., Xu, X., & Liu, X. (2021). A chickpea genetic variation map based on the sequencing of 3,366 genomes. Nature, 599(7886), 622-627. https://doi.org/10.1038/s41586-021-04066-1
Varshney, Rajeev K, et al. "A chickpea genetic variation map based on the sequencing of 3,366 genomes." Nature vol. 599,7886 (2021): 622-627. doi: https://doi.org/10.1038/s41586-021-04066-1
Varshney RK, Roorkiwal M, Sun S, Bajaj P, Chitikineni A, Thudi M, Singh NP, Du X, Upadhyaya HD, Khan AW, Wang Y, Garg V, Fan G, Cowling WA, Crossa J, Gentzbittel L, Voss-Fels KP, Valluri VK, Sinha P, Singh VK, Ben C, Rathore A, Punna R, Singh MK, Tar'an B, Bharadwaj C, Yasin M, Pithia MS, Singh S, Soren KR, Kudapa H, Jarquín D, Cubry P, Hickey LT, Dixit GP, Thuillet AC, Hamwieh A, Kumar S, Deokar AA, Chaturvedi SK, Francis A, Howard R, Chattopadhyay D, Edwards D, Lyons E, Vigouroux Y, Hayes BJ, von Wettberg E, Datta SK, Yang H, Nguyen HT, Wang J, Siddique KHM, Mohapatra T, Bennetzen JL, Xu X, Liu X. A chickpea genetic variation map based on the sequencing of 3,366 genomes. Nature. 2021 Nov;599(7886):622-627. doi: 10.1038/s41586-021-04066-1. Epub 2021 Nov 10. PMID: 34759320; PMCID: PMC8612933.
Copy Download .nbib Format: NLM
Comparison of machine learning and deep learning for view identification from cardiac magnetic resonance images.

Clinical imaging

Chauhan D, Anyanwu E, Goes J, Besser SA, Anand S, Madduri R, Getty N, Kelle S, Kawaji K, Mor-Avi V, Patel AR.
PMID: 34813989
Clin Imaging. 2021 Nov 19;82:121-126. doi: 10.1016/j.clinimag.2021.11.013. Epub 2021 Nov 19.

BACKGROUND: Artificial intelligence is increasingly utilized to aid in the interpretation of cardiac magnetic resonance (CMR) studies. One of the first steps is the identification of the imaging plane depicted, which can be achieved by both deep learning (DL)...

Cite
Chauhan D, Anyanwu E, Goes J, et al. Comparison of machine learning and deep learning for view identification from cardiac magnetic resonance images. Clin Imaging. 2021;82:121-126doi: 10.1016/j.clinimag.2021.11.013.
Chauhan, D., Anyanwu, E., Goes, J., Besser, S. A., Anand, S., Madduri, R., Getty, N., Kelle, S., Kawaji, K., Mor-Avi, V., & Patel, A. R. (2021). Comparison of machine learning and deep learning for view identification from cardiac magnetic resonance images. Clinical imaging, 82121-126. https://doi.org/10.1016/j.clinimag.2021.11.013
Chauhan, Daksh, et al. "Comparison of machine learning and deep learning for view identification from cardiac magnetic resonance images." Clinical imaging vol. 82 (2021): 121-126. doi: https://doi.org/10.1016/j.clinimag.2021.11.013
Chauhan D, Anyanwu E, Goes J, Besser SA, Anand S, Madduri R, Getty N, Kelle S, Kawaji K, Mor-Avi V, Patel AR. Comparison of machine learning and deep learning for view identification from cardiac magnetic resonance images. Clin Imaging. 2021 Nov 19;82:121-126. doi: 10.1016/j.clinimag.2021.11.013. Epub 2021 Nov 19. PMID: 34813989.
Copy Download .nbib Format: NLM
Live-Cell Imaging Shows Uneven Segregation of Extrachromosomal DNA Elements and Transcriptionally Active Extrachromosomal DNA Hubs in Cancer.

Cancer discovery

Yi E, Gujar AD, Guthrie M, Kim H, Zhao D, Johnson KC, Amin SB, Costa ML, Yu Q, Das S, Jillette N, Clow PA, Cheng AW, Verhaak RGW.
PMID: 34819316
Cancer Discov. 2021 Nov 24; doi: 10.1158/2159-8290.CD-21-1376. Epub 2021 Nov 24.

Oncogenic extrachromosomal DNA elements (ecDNA) play an important role in tumor evolution, but our understanding of ecDNA biology is limited. We determined the distribution of single-cell ecDNA copy number across patient tissues and cell line models and observed how...

Cite
Yi E, Gujar AD, Guthrie M, et al. Live-Cell Imaging Shows Uneven Segregation of Extrachromosomal DNA Elements and Transcriptionally Active Extrachromosomal DNA Hubs in Cancer. Cancer Discov. 2021;doi: 10.1158/2159-8290.CD-21-1376.
Yi, E., Gujar, A. D., Guthrie, M., Kim, H., Zhao, D., Johnson, K. C., Amin, S. B., Costa, M. L., Yu, Q., Das, S., Jillette, N., Clow, P. A., Cheng, A. W., & Verhaak, R. G. W. (2021). Live-Cell Imaging Shows Uneven Segregation of Extrachromosomal DNA Elements and Transcriptionally Active Extrachromosomal DNA Hubs in Cancer. Cancer discovery, . https://doi.org/10.1158/2159-8290.CD-21-1376
Yi, Eunhee, et al. "Live-Cell Imaging Shows Uneven Segregation of Extrachromosomal DNA Elements and Transcriptionally Active Extrachromosomal DNA Hubs in Cancer." Cancer discovery vol. (2021). doi: https://doi.org/10.1158/2159-8290.CD-21-1376
Yi E, Gujar AD, Guthrie M, Kim H, Zhao D, Johnson KC, Amin SB, Costa ML, Yu Q, Das S, Jillette N, Clow PA, Cheng AW, Verhaak RGW. Live-Cell Imaging Shows Uneven Segregation of Extrachromosomal DNA Elements and Transcriptionally Active Extrachromosomal DNA Hubs in Cancer. Cancer Discov. 2021 Nov 24; doi: 10.1158/2159-8290.CD-21-1376. Epub 2021 Nov 24. PMID: 34819316.
Copy Download .nbib Format: NLM
Imaging and Biomarker Approaches to HCC Surveillance.

Clinical liver disease

Nathani P, Singal AG.
PMID: 34386203
Clin Liver Dis (Hoboken). 2021 Aug 05;17(6):401-404. doi: 10.1002/cld.1066. eCollection 2021 Jun.

No abstract available.

Cite
Nathani P, Singal AG. Imaging and Biomarker Approaches to HCC Surveillance. Clin Liver Dis (Hoboken). 2021;17(6):401-404doi: 10.1002/cld.1066.
Nathani, P., & Singal, A. G. (2021). Imaging and Biomarker Approaches to HCC Surveillance. Clinical liver disease, 17(6), 401-404. https://doi.org/10.1002/cld.1066
Nathani, Piyush, and Singal, Amit G. "Imaging and Biomarker Approaches to HCC Surveillance." Clinical liver disease vol. 17,6 (2021): 401-404. doi: https://doi.org/10.1002/cld.1066
Nathani P, Singal AG. Imaging and Biomarker Approaches to HCC Surveillance. Clin Liver Dis (Hoboken). 2021 Aug 05;17(6):401-404. doi: 10.1002/cld.1066. eCollection 2021 Jun. PMID: 34386203; PMCID: PMC8340352.
Copy Download .nbib Format: NLM
Associations of Ultrasound LI-RADS Visualization Score With Examination-, Sonographer-, and Radiologist-Factors: Retrospective Assessment in Over 10,000 Examinations.

AJR. American journal of roentgenology

Fetzer DT, Browning T, Xi Y, Yokoo T, Singal AG.
PMID: 34910539
AJR Am J Roentgenol. 2021 Dec 15; doi: 10.2214/AJR.21.26735. Epub 2021 Dec 15.

No abstract available.

Cite
Fetzer DT, Browning T, Xi Y, et al. Associations of Ultrasound LI-RADS Visualization Score With Examination-, Sonographer-, and Radiologist-Factors: Retrospective Assessment in Over 10,000 Examinations. AJR Am J Roentgenol. 2021;doi: 10.2214/AJR.21.26735.
Fetzer, D. T., Browning, T., Xi, Y., Yokoo, T., & Singal, A. G. (2021). Associations of Ultrasound LI-RADS Visualization Score With Examination-, Sonographer-, and Radiologist-Factors: Retrospective Assessment in Over 10,000 Examinations. AJR. American journal of roentgenology, . https://doi.org/10.2214/AJR.21.26735
Fetzer, David T, et al. "Associations of Ultrasound LI-RADS Visualization Score With Examination-, Sonographer-, and Radiologist-Factors: Retrospective Assessment in Over 10,000 Examinations." AJR. American journal of roentgenology vol. (2021). doi: https://doi.org/10.2214/AJR.21.26735
Fetzer DT, Browning T, Xi Y, Yokoo T, Singal AG. Associations of Ultrasound LI-RADS Visualization Score With Examination-, Sonographer-, and Radiologist-Factors: Retrospective Assessment in Over 10,000 Examinations. AJR Am J Roentgenol. 2021 Dec 15; doi: 10.2214/AJR.21.26735. Epub 2021 Dec 15. PMID: 34910539.
Copy Download .nbib Format: NLM
The validity of mobile applications to facilitate patient care provided to cancer patients: opportunities and limitations.

Recent patents on anti-cancer drug discovery

Amawi H, Alazzam S, Alzanati T, Altamimi N, Hammad A, Alzoubi KH, Ashby JCR, Tiwari AK.
PMID: 34323199
Recent Pat Anticancer Drug Discov. 2021 Jul 28; doi: 10.2174/1574892816666210728122304. Epub 2021 Jul 28.

BACKGROUND: The use of health-related applications (apps) on smartphones has become widespread. This is especially of value during the ongoing SAR-COV-2 pandemic, where the accessibility for health care services has been greatly limited. Patients with free access to apps...

Cite
Amawi H, Alazzam S, Alzanati T, et al. The validity of mobile applications to facilitate patient care provided to cancer patients: opportunities and limitations. Recent Pat Anticancer Drug Discov. 2021;doi: 10.2174/1574892816666210728122304.
Amawi, H., Alazzam, S., Alzanati, T., Altamimi, N., Hammad, A., Alzoubi, K. H., Ashby, J. C. R., & Tiwari, A. K. (2021). The validity of mobile applications to facilitate patient care provided to cancer patients: opportunities and limitations. Recent patents on anti-cancer drug discovery, . https://doi.org/10.2174/1574892816666210728122304
Amawi, Haneen, et al. "The validity of mobile applications to facilitate patient care provided to cancer patients: opportunities and limitations." Recent patents on anti-cancer drug discovery vol. (2021). doi: https://doi.org/10.2174/1574892816666210728122304
Amawi H, Alazzam S, Alzanati T, Altamimi N, Hammad A, Alzoubi KH, Ashby JCR, Tiwari AK. The validity of mobile applications to facilitate patient care provided to cancer patients: opportunities and limitations. Recent Pat Anticancer Drug Discov. 2021 Jul 28; doi: 10.2174/1574892816666210728122304. Epub 2021 Jul 28. PMID: 34323199.
Copy Download .nbib Format: NLM
A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer.

Urology

Bhattu AS, Zappala SM, Parekh DJ, Punnen S.
PMID: 33217456
Urology. 2021 Feb;148:53-58. doi: 10.1016/j.urology.2020.11.008. Epub 2020 Nov 18.

OBJECTIVE: To evaluate the 4Kscore test's low risk cut-off of 7.5% as the indication to proceed with a prostate biopsy by combining data from 2 independent prospective multicentre trials in the United States which have validated the 4Kscore test...

Cite
Bhattu AS, Zappala SM, Parekh DJ, et al. A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer. Urology. 2020;148:53-58doi: 10.1016/j.urology.2020.11.008.
Bhattu, A. S., Zappala, S. M., Parekh, D. J., & Punnen, S. (2021). A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer. Urology, 14853-58. https://doi.org/10.1016/j.urology.2020.11.008
Bhattu, Amit S, et al. "A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer." Urology vol. 148 (2021): 53-58. doi: https://doi.org/10.1016/j.urology.2020.11.008
Bhattu AS, Zappala SM, Parekh DJ, Punnen S. A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer. Urology. 2021 Feb;148:53-58. doi: 10.1016/j.urology.2020.11.008. Epub 2020 Nov 18. PMID: 33217456.
Copy Download .nbib Format: NLM
Showing 2245 to 2254 of 2254 entries